section name header

Pronunciation

flib-AN-ser-in

Classifications

Therapeutic Classification: sexual dysfunction agents

Indications

REMS


Action

  • May be explained by agonist activity at 5–HT1A receptors and antagonist activity at 5–HT2A receptors; also has moderate antagonist activity at 5–HT2B, 5–HT2C, and dopamine D4 receptors.
Therapeutic effects:
  • sexual desire with distress and interpersonal dysfunction.

Pharmacokinetics

Absorption: Moderately absorbed (33%) following oral administration.

Distribution: Unknown.

Protein Binding: 98%.

Metabolism/Excretion: Primarily metabolized in the liver, via the CYP3A4 isoenzyme, and to a lesser extent by the CYP2C19 isoenzyme; the CYP2C19 isoenzyme exhibits genetic polymorphism; poor metabolizers may have significantly flibanserin concentrations and an risk of adverse effects. 44% excreted in urine, 51% in feces almost entirely as metabolites, which do not appear to be pharmacologically active.

Half-Life: 11 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POwithin 1 hr1 hr24 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Natural-Natural Products:

Drug-Food:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Addyi